Drug development
Genomic information about an individual can be of considerable importance to the process of developing drugs while they await FDA approval for public use. When determining whether a patient should be included or excluded in the final stages of a clinical trial, a detailed understanding of a patient’s genetic make-up is invaluable [13] Identifying patients who will benefit most from a clinical trial will increase patient safety and endanger adverse effects from the testing product, and smaller and faster trials will entail lower costs [19]. Furthermore, drugs that are ineffective for a larger portion of the population can gain approval by the FDA depending on the personal genomes used to evaluate the effectiveness and necessity of the specific medicine, even though the majority may not require it.